I maintain a bullish outlook on gold, reiterating a $6,000/oz target despite recent price declines and investor outflows. GLD ...
Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for ophthalmic indications. Its lead product ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results